Trial · NCT03139604
Results by group55
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 55
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Overall Response Rate Based on Center for International Blood and Marrow Transplant Research (CIBMTR) Response Index | Itacitinib Plus Corticosteroids | 74.0 | 95% Confidence Interval 67.6 to 79.7 | Percentage of Participants | |
| Overall Response Rate Based on Center for International Blood and Marrow Transplant Research (CIBMTR) Response Index | Placebo Plus Corticosteroids | 66.4 | 95% Confidence Interval 59.7 to 72.6 | Percentage of Participants | |
| Nonrelapse Mortality | Itacitinib Plus Corticosteroids | 6 Months | 36 | participants | |
| Nonrelapse Mortality | Placebo Plus Corticosteroids | 6 Months | 37 | participants | |
| Nonrelapse Mortality | Itacitinib Plus Corticosteroids | 9 Months | 46 | participants | |
| Nonrelapse Mortality | Placebo Plus Corticosteroids | 9 Months | 45 | participants | |
| Nonrelapse Mortality | Itacitinib Plus Corticosteroids | 12 Months | 51 | participants | |
| Nonrelapse Mortality | Placebo Plus Corticosteroids | 12 Months | 52 | participants | |
| Nonrelapse Mortality | Itacitinib Plus Corticosteroids | 24 Months | 56 | participants | |
| Nonrelapse Mortality | Placebo Plus Corticosteroids | 24 Months | 52 | participants | |
| Duration of Response | Itacitinib Plus Corticosteroids | 587 | 95% Confidence Interval 513 to NA | days | |
| Duration of Response | Placebo Plus Corticosteroids | NA | 95% Confidence Interval NA to NA | days | |
| Cmax of Itacitinib When Administered in Combination With Corticosteroids | Itacitinib Plus Corticosteroids | 796 | Standard Deviation 642 | nM | |
| Cmin of Itacitinib When Administered in Combination With Corticosteroids | Itacitinib Plus Corticosteroids | 72.5 | Standard Deviation 121 | nM | |
| Tmax of Itacitinib When Administered in Combination With Corticosteroids | Itacitinib Plus Corticosteroids | 2.1 | Full Range 0.83 to 5.3 | hrs | |
| AUC of Itacitinib When Administered in Combination With Corticosteroids | Itacitinib Plus Corticosteroids | 6720 | Standard Deviation 6210 | nM*h | |
| CL/F of Itacitinib When Administered in Combination With Corticosteroids | Itacitinib Plus Corticosteroids | 104 | Standard Deviation 76.7 | L/h | |
| Time to Response | Itacitinib Plus Corticosteroids | 9.9 | Standard Deviation 6.25 | days | |
| Time to Response | Placebo Plus Corticosteroids | 10.1 | Standard Deviation 5.37 | days | |
| Relapse Rate of Malignant and Nonmalignant Hematologic Disease | Itacitinib Plus Corticosteroids | 12.4 | percentage |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03139604/results